Professor Augusto Pessina Brief CV

Size: px
Start display at page:

Download "Professor Augusto Pessina Brief CV"

Transcription

1 Professor Augusto Pessina Brief CV Present Position Associated Professor Professor of Microbiology Faculty of Medicine of the University of Milan. Head of Cell Culture Laboratory,Section of Microbiology, Department of Biomedical Surgical and Dental Sciences.President Gruppo Italiano Staminali Mesenchimali (GISM).Past President: Associazione Italiana di Colture Cellulari (AICC) Teaching and research: Graduated in Biological Science,University of Milan (1971). Specialized in Medical Microbiology, University of Milan (1978).Assistant Researcher at Centre of Cellular Pathology of the National Council for Research, Milan ( ).Selected as Italian Participant to the Second training course on experimental cancer research of UICC (Amsterdam,1975).Appointed by the National Board of Education of Italy to the Department of Pathology, Hospital of Desio for studying the effect of Dioxine (TCDD) on immune system of children accidentally exposed to the toxic in Seveso ( ). Professor of General Pathology at School of Pharmacology, Faculty of Pharmacy, University of Milan.( ). Appointment by the Board of Education to the Institute of Medical Microbiology, University of Milan for developing new educational training ( ). External Examiner for PhD thesis at the School of Biological Sciences, National Cell and Tissue Culture Centre Dublin City University (Ireland) (1994,2011).Reporter of a PhD thesis at the Universitè de Bretagne Occidentale (UBO) France(2004). Management of scientific events Organizer and promoter of many national and international scientific events as congress, meeting, workshop and courses.co-organizer with Prof. Martin Clynes ( Dublin City University-Ireland) of the "First International Meeting on Drug Resistance in Cancer" (1995).Representative of the division "Cancer sensitivity and drug resistance" of the European Tissue Culture Society (ETCS) ( ). Chairman of the Italian Committee of the 3 rd World Congress on Alternatives and Animal use in life science. Bologna 1999.Member of the Scientific Advisory Board of the National Institute for Cellular Biotechnology (NICB) of Dublin City University ( Ireland) ( ).Co- President of the 46P thp ETCS meeting held in Verona ( 2006).President of the Italian Association for Cell Culture (AICC) ( ).Member of the International Scientific Societies and peer reviewer of may international scientific journals. Scientific responsible of the following European Commission projects: In vitro system for testing haematotoxicity ( ). Inhibition of CFU-E/BFU-E by different classes of chemicals: a comparative study on direct effects on progenitors and the effect on longterm exposure of bone marrow ( ). In vitro tests for haematotoxicity: prevalidation and validation of GM-CFU assay for predicting acute neutropenia ( ). Development and prevalidation of the in vitro assays for the prediction of thrombocytopenia (Italian Operative Unit ) Purification and regulation of haematopoietic stem cells: in vitro studies ( )."Plasticity of adult stem cells in cord blood" ( ) Prevalidation of rat CFU-GM assay ( ) Scientific Unit Responsible inside the projects Transplant of adult stem cells in regenerative cellular therapy of Blood Plan of Regione Lombardia ( ). Role of human mesenchymal stem cells in tumor angiogenesis of AIRC ( Associazione Italiana per la Ricerca sul Cancro) ( ). LoCMeD - Lab on Chip for testing Myelotoxic effect of Drugs and chemicals (Fund from Fondazione Cariplo) ( ). " Mesenchymal stromal cells loaded with Paclitaxel home glioblastoma vasculature and inhibit tumor growth of AIRC ( Associazione Italiana per la Ricerca sul Cancro) ( ) 1

2 Some notes on research activity particularly related to hematotoxicity The experience of Dr Augusto Pessina in the field of hematotoxicity originated in the years 1970 with studies concerning the relation between the neoplastic growth and the haematopoietic disorders observed in tumor bearing mice. He developed specific in vitro techniques for studying the effect exerted by factors produced by tumor cells on the proliferation and differentiation of myeloid precursors and in his laboratory were isolated cytokines active on the haematopoietic progenitors (Int. J. Immunopharmacol. 7,549,1985; Blut,55,499,1987). At the first UICC training course organized in Amsterdam on 1975 had as teacher Donald Melcalf (who is considered the pioneer of the in vitro studies on proliferation and differentiation of haematopoietic progenitors) and the possibility to improve the techniques for assessing the "in vitro" growth of granulocyte-macrophage committed cells (GM-CFU). Dr. Pessina has been involved five years ( )in an international project at the Hospital of Desio (Milan,Italy) for studying the haematotoxic effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on the immune system of children accidentally exposed to the toxic in the area of Seveso ( ICMESA accident). Since 1981 he runs a Laboratory of Cell Culture at the Institute of Microbiology (Milan) and his researches have been continued on the relationship between tumor growth and the production of cytokines ( CSFs) involved in the proliferation- differentiation of pluripotent stem cells ( CFU-s) and committed progenitors ( CFU-C) in haematopoiesis ( J. Cancer Res.Clin. Oncol.,102,235,1982; Oncology 39,391,1982; J.Natl.Cancer Inst., 76,1095,1986). In his laboratory have been established twi new cell lines: a stromal cell line obtained from murine bone marrow adherent cells (SR-4987), ( Cytotechnology 8,93,1992 ) available by ATCC (CRL-2028) and a subclone of WEHI-3B leukemia cells resistant to ciprofloxacin ( Cancer J.,6,291,1993) due to a mutation of topoisomerase II. By using SR-4987 cells has been standardized a new "in vitro" method for testing FGFs in biological samples and developed an in vitro model to investigate the role of stromal cells in the modulation of drug induced hematotoxicity (Life Sci.,65,513,1999). Researches of the response of different cellular models the biological effects of microbial toxins demonstrated that the proliferative block exerted by Cholera Toxin may be dependent or not to the camp accumulation and that there are membrane ganglioside with different affinity to CT ad capacity to transduce the signal. A stable mutant of a leukemia cell line (WEHI-3B) has been established by Dr Pessina which lacks of the Gal-GalNac-GM1b ganglioside that is a very important functional receptor in WEHI-3b cells ( Cell.Mol.Biol.,44, ,1998. Mol.Cell.Biochem,152, ,1995 Mol.Cell Biochem. 233,19-26, 2002) By using GM-CFU techniques Dr Pessina studied the effect of topoisomerase inhibitors, antibiotics and microbial toxins on different animal cell models ( J.Antimicrob. Chemother., 24,203,1989; Biochim.Bioph. Acta,1013,206,1989 ; Mol. Cell Biochem.,152,1995). Since 1994 he managed EC contracts concerning the development of alternative methods for hematototoxicity testing and coordinated projects of prevalidation and validation of standard operating procedure based on the use of multipotent stem cells as progenitors of granulocyte-macrophages (GM- CFU), megakaryocytes (Mk-CFU) and erythrocytes (CFU-E). Based on these results ( Toxicological Sciences, 75, ,2003 ) the ECVAM Scientific Advisory Committee (ESAC) on 2006 unanimously endorsed the CFU-GM assay for predicting acute neutropenia in humans. Recently a study has been conducted to prevalidate the GM-CFU assay with frozen bone marrow cells of rat that can contribute to REACH programme ( Altern.To Lab.Animals 37: ,2009. Altern.To Lab.Animals 38: ,2010). Since 2004 the cell culture laboratory of Dr Pessina is involved in studies on the therapeutic potential of stem cells and on assays to assess their safety with a particular attention to the microbiological risks (BBRC, 323: ,2004, Crit.Rev.Microbiol, 34:1-12,2008,Transpl Infect Dis.11 : ,2009 ;,Cell Biol. Int. 34: ,2010). More recent his group have indicated that MSCs can be used as drug carrier. By using a cancer drug ( Paclitaxel) has been demonstrated that human MSCs are able to uptake and release the drug and that PTX loaded MSCs produced a dramatic inhibition of tumor growth both in vitro and in vivo. PLoS ONE 6(12): e doi: /journal.pone In recent paper his laboratori demonstrated that drugs can be released by mesenchymal stem cells into 2

3 microvesicles/exosomes opening new possible biotechnology application for the production of more bioavailable molecules able to support new therapeutic approaches A selection of some publications of the last 15 years PASCUCCI L, COCCÈ V, BONOMI A, AMI D, CECCARELLI P, CIUSANI E, VIGANÒ L, LOCATELLI A, SISTO F, DOGLIA SM, PARATI E, BERNARDO ME, MURACA M, ALESSANDRI G, BONDIOLOTTI G, PESSINA A. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. Journal Controlled Release 192: , SISTO F, BONOMI A, CAVICCHINI L, COCCÈ V, SCALTRITO MM, BONDIOLOTTI G, ALESSANDRI G, PARATI E, PESSINA A. Human mesenchymal stromal cells can uptake and release ciprofloxacin, acquiring in vitro anti-bacterial activity. Cytotherapy. 2014,16: MARIOTTI M, COLOGNATO R, RIMOLDI M, RIZZETTO M, SISTO F, COCCE V, BONOMI A, PARATI E, ALESSANDRI G, BAGNATI R, PESSINA A. Mesenchymal Stromal Cells Uptake And Release Paclitaxel Without Reducing Its Anticancer Activity. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, vol. 13, p , ISSN: , doi: / S. NAVONE, L. PASCUCCI, M. DOSSENA, A. FERRI, G. INVERNICI, F. ACERBI, S. CRISTINI, G. BEDINI, V. TOSETTI, V. CESERANI, A. BONOMI, A. PESSINA, G. FREDDI, A. ALESSANDRINO, P. CECCARELLI, R. CAMPANELLA, G. MARFIA, G. ALESSANDRI, E.A. PARATI (2014). Decellularized silk fibroin scaffold primed with adipose mesenchymal stromal cells improves wound healing in diabetic mice. STEM CELL RESEARCH & THERAPY, vol. 5, p. 1-15, ISSN: , doi: /scrt396 ANTONELLA CONFORTI, SIMONE BIAGINI, NADIA STARC, ALESSANDRA PROIA,AUGUSTO PESSINA, GIULIO ALESSANDRI, FRANCO LOCATELLI, MARIA ESTER BERNARDO. Human mesenchymal stromal cells primed with paclitaxel, apart from displaying anti-tumor activity, maintain their immune regulatory functions in vitro. Cytotherapy, 2014; 16: 868e870 pen Access LUIGI BALDUCCI, ANTONELLA BLASI, MARILISA SALDARELLI, ANTONIO SOLETI, AUGUSTO PESSINA, ARIANNA BONOMI,VALENTINA COCCÈ, MARTA DOSSENA, VALENTINA TOSETTI, VALENTINA CESERANI, STEFANIA ELENA NAVONE,MARIA LAURA FALCHETTI, EUGENIO AGOSTINO PARATI AND GIULIO ALESSANDRI. Immortalization of human adipose-derivedstromal cells: production of cell lines with highgrowth rate, mesenchymal marker expression andcapability to secrete high levels of angiogenic factors. Stem Cell Research & Therapy 2014, 5:63 M. RASPONI, A. GAZANEO, A. BONOMI, P. OCCHETTA, L. CAVICCHINI, V. COCCE, G. B. FIORE, A.PESSINA AND A. REDAELLI. Lab-on-Chip for testing Myelotoxic effect of drugs and chemicals GNB2014, June 25th-27th 2014, Pavia, Italy. PESSINA A, COCCÈ V, PASCUCCI L, BONOMI A, CAVICCHINI L, SISTO F, FERRARI M, CIUSANI E, CROVACE A, FALCHETTI ML, ZICARI S, CARUSO A, NAVONE S, MARFIA G, BENETTI A, CECCARELLI P, PARATI E, ALESSANDRI G. Mesenchymal stromal cells primed 3

4 with Paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of leukaemia-bearing mice. Br J Haematol. 2013; 160: BONOMI A, COCCÈ V, CAVICCHINI L, SISTO F, DOSSENA M, BALZARINI P, PORTOLANI N, CIUSANI E, PARATI E, ALESSANDRI G, PESSINA A. Adipose-tissuederived stromal cells primed in vitro with paclitaxel acquires anti-tumor activity. Int J Immunopathol Pharmacol. 2013:26, PESSINA A, BONOMI A, CIUSANI E, PASCUCCI L, PARATI E, ALESSANDRI G. Mesenchymal stromal cells used for carrying and delivering Paclitaxel in Paclitaxel: Biosynthesis, Mechanisms of Action and Clinical Uses, D. Morales, Nova Science Publishers 2013, pp PESSINA A, BONOMI A, PARATI E, PALLINI R, ALESSANDRI G. Primed mesenchymal stromal cells for cancer therapy. In Stem Cell Therapeutics for Cancer. Ed Khalid Shah, Wiley Blackwell 2013, pp LAURA DE GIROLAMO, ENRICO LUCARELLI2, GIULIO ALESSANDRI3, MARIA ANTONIETTA AVANZINI4, MARIA ESTER BERNARDO,ETTORE BIAGI, ANNA TERESA BRINI, GIOVANNA D AMICO, FRANCA FAGIOLI, IVANA FERRERO10, FRANCO LOCATELLI,RITA MACCARIO, MARIO MARAZZI, ORNELLA PAROLINI, AUGUSTO PESSINA AND MARIA LUISA TORRE. Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm.Efficacy and Critical Aspects in Cell Therapy. Current Pharmaceutical Design, 2013, 19, S. DUCHI, P. DAMBRUOSO,E. MARTELLA,G. SOTGIU,A. GUERRINI, E. LUCARELLI,A. PESSINA,V. COCCÈ,A. BONOMI,AND G. VARCHI. Thiophene-Based Compounds as Fluorescent Tags to Study Mesenchymal Stem Cell Uptake and Release of Taxanes BIOCONJUGATE CHEMISTRY, vol. 25, p , ISSN: , doi: /bc AUGUSTO PESSINA,VALENTINA COCCÈ, ARIANNA BONOMI, LOREDANA CAVICCHINI, FRANCESCA SISTO, MAURA FERRARI,EMILIO CIUSANI, STEFANIA NAVONE, GIOVANNI MARFIA, EUGENIO PARATI AND GIULIO ALESSANDRI. Human Skin-Derived Fibroblasts Acquire In Vitro Anti-Tumor Potential after Priming with Paclitaxel.Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, PESSINA A.,SISTO F.,COCCE V.,CAVICCHINI L.,CIUSANI E.,GRIBALDO L., BONOMI. A mesenchymal stromal cell line resistant to paclitaxel that spontaneously differentiates into Osteoblast-like cells. Cell Biol Toxicol 27: ,2011. PESSINA A., BONOMI A, COCCÈ V, INVERNICI G, NAVONE S, CAVICCHINI L et al.. Mesenchymal Stromal cells primed with paclitaxel provide a new approach for cancer therapy. PLoS ONE 6(12): e28321.doi: /journal.pone (2011). PESSINA A.,BONOMI A.,CAVICCHINI L.,ALBELLA B., CERRATO L.,PARENT-MASSIN D.,SIBIRIL Y.,PARCHMENT R.,BEHRSING H.,VERDERIO P., PIZZAMIGLIO S.,GIANGRECO M., BAGLIO C.,COCCÈ V.,SISTO F. and GRIBALDO L..Prevalidation of Rat GM-CFU Assay for In Vitro Toxicology Application. Altern.To Lab.Animals (ATLA) 38: ,2010. PESSINA A., BONOMI A.,SISTO F., BAGLIO C., CAVICCHINI L.,CIUSANI L.,COCCÉ V., GRIBALDO L.. CD45+/CD133+ positive cells expanded from umbilical cord blood expressing pdx-1 and markers of pluripotency. Cell Biol. Int. 34: ,

5 PESSINA A. Cellule staminali pluripotenti. Le prospettive delle ipsc restano problematiche Emmeciquadro 38: 27-30,2010. PESSINA A., BONOMI A. Prediction of potential drug myelotoxicity by in vitro assays on haematopoietic progenitors. In Methods in Bioengineering: Alternative technologies to animal testing" eds Tim Maguire and Eric Novik Eds,Artech House Boston-London. Pages ,2010. LULLI M, DI GESUALDO F.,WITORT E.,PESSINA A.,CAPACCIOLI S.. Cell death: physiopathological and therapeutic implications. Cell Death Dis. 1: e30; doi: /cddis PESSINA A.,PARENT-MASSIN D., ALBELLA B.,VAN DEN HEUVEL R.,CASATI S.,CROERA C.,MALERBA I.,SIBIRIL Y.,GOMEZ.S., DE SMEDT.,GRIBALDO L.. Application of human CFU-Mk assay to predict potential thrombocytotoxicity of drugs. Toxicology in Vitro, 23: ,2009. PESSINA A., BONOMI A., BAGLIO C., CAVICCHINI L., GRIBALDO Refinement and Optimisation of the rat CFU-GM assay to use cryopreserved bone marrow cells for in vitro toxicology application. Altern.To Lab.Animals (ATLA) 37: ,2009. PESSINA A.,BONOMI A.,COCCÈ V., BERNARDO M.E., COMETA A.M., FERRARI M., SISTO F.,CAVICCHINI L.,LOCATELLI F. Assessment of human herpesvirus-6 infection in mesenchymal stromal cells ex vivo expanded for clinical use.transpl Infect DisT.11 : ,2009. PESSINA A. BONOMI A., BAGLIO C.,CAVICCHINI L.,SISTO F., NERI MG.,GRIBALDO L..Microbiological Risk Assessment In Stem Cell Manipulation. Crit.Rev.Microbiol, 34:1-12,2008 PESSINA A., BONOMI A.,CASATI S.,COLLOTTA A.,CROERA C.,MARAFANTE E.,PALITTI F.,GRIBALDO L.. Mitochondrial function, apoptosis and cell-cycle delay in the WEHI-3B leukemia cell line and its variant ciprofloxacin-resistant WEHI-3B/CPX. Cell Prolif.,40, ,2007. PESSINA A., BONOMI A. CFU-GM assay for evaluation of drug Myelotoxic Activity Curr.Prot.Toxicol. 34: , Eds. John Wiley & Sons,Inc., PESSINA A., TURLIZZI E., BONOMI A., GUIZZARDI F., CAVICCHINI L.,CROERA C., BAREGGI S..In vitro toxicity of clozapine,olanzapine and quetiapine on granulocyte-macrophage progenitors(gm- CFU). Pharmacopsychiatry,39,20-22,2006. PESSINA A., CROERA C.,SAVALLI N.,BONOMI A.,CAVICCHINI L.P 1P,TURLIZZI E., GUIZZARDI F.,GUIDO L.,DAPRAI L.,P 1P NERI MG..Bcl-2 down modulation in WEHI-3B/CTRES cells resistant to Cholera Toxin (CT)-induced apoptosis. Cell Res. 16: ,2006 PESSINA A., and GRIBALDO L..The key role of adult stem cells: therapeutic perspectives. Curr. Med. Res. Opin.,22, ,2006 PESSINA A., MALERBA I., GRIBALDO L. Haematotoxicity testing by cell clonogenic assay in drug development and preclinical trials Curr.Pharmaceut.Design 11, , PESSINA A., CROERA C., BAYO M., MALERBA I., PASSARDI L., CAVICCHINI L., 5

6 NERI M.G., GRIBALDO L. A methylcellulose microculture assay for the in vitro assessment of drug toxicity on granulocyte- macrophage progenitors (CFU-GM). ATLA 32:17-23, 2004 PESSINA A.,ELETTI B.,CROERA C.,SAVALLI N.,DIODOVICH C.,GRIBALDO L.. Pancreas developing markers expressed on human mononucleated umbilical cord blood cells.biochem Biophys. Res. Comm. 323: ,2004 PESSINA A., ALBELLA B., BAYO M., BUEREN J.,.BRANTOM P., CASATI S.,. CROERA C.,GAGLIARDI G FOTI P, PARCHMENT R., PARENT-MASSIN D., SCHOETERS G., SIBIRIL Y.,VAN DEN HEUVEL R.,.GRIBALDO L. Application of the CFU-GM assay to predict acute drug-induced neutropenia:an international blind trial to validate a prediction model for the maximum tolerated dose(mtd) of myelosuppressive xenobiotics. Toxicological Sciences, 75, ,2003. ROSEEUW E.,COESSENS V.,BALAZUC AM.,LAGRANDERIE M.,CHAVAROT P., PESSINA A., NERI MG., SCHACHT E.,MARCHAL G., DOMURADO D.. Synthesis, degradation and antimicrobial properties of targeted macromolecular prodrugs of norfloxacin. Antimicrob. Agents Chemother.,47, ,2003. PESSINA A., BAYO M.,CROERA C.,MERINGOLO F.,NERI MG.MONTESISSA L., RAIMONDI A. In vitro sensitivity of Human Gastric Cancer Cells( HGC-27) to Helicobacter pylori cytotoxin. Scand. J. Gastroenterol. 12: ,2003. PESSINA A., GIULIANI A., CROERA C., FOTI P., MASCOLO L. GAGLIARDI G. NERI MG. Selection of a WEHI-3B leukemia cell subclone resistant to inhibition by cholera toxin. Mol.Cell Biochem., 233,19-26,2002. PESSINA A., GAGLIARDI G.,CROERA C.FOTI P.,DASSI C.BRAMBILLA P.,NERI MG..Secretion of basic fibroblast growth factor (FGF-2) by WEHI-3B myelomonocitic leukemia cells. Growth Factors, 20, ,2002. PESSINA A.,RAIMONDI A:;CROERA C:, ACCHINI M:,MINEO E.,FOTI P:,NERI MG: Altered DNA cleavage activity of topoisomerase II from WEHI-3B leukemia cells resistant to ciprofloxacin. Anti-Cancer Drugs,12, ,2001 PESSINA A,RAIMONDI A.CERRI A. PICCIRILLO M, NERI MG, CROERA C.,FOTI P.,BERTI E. High sensitivity of human epidermal keratinocytes (HaCaT) to topoisomerase inhibitors. Cell Proliferation,34, ,2001. PESSINA A., ALBELLA B., BUEREN J.,.BRANTOM P., CASATI S.,.CROERA C., GAGLIARDI G., GRIBALDO L, FOTI P., PARCHMENT R., PARENT-MASSIN D., SCHOETERS G., SIBIRIL Y.,VAN DEN HEUVEL Prevalidation of a model for predicting acute neutropenia by Colony Forming Unit- Granulocyte/Macrophage CFU-GM) assay Toxicology in Vitro, 15, ,2001. GRIBALDO L, MALERBA I.,COLLOTTA A.,CASTI S.,PESSINA A.. Inhibition of CFGU-e/BFU-E by 3 -azido- 3 -deoxythymidine,chlorpropamide and protoporphirin IX zinc (II): a comparison between direct exposure of progenitor cells and long-term exposure of bone marrow. Toxicological Sciences 58, ,2000. PESSINA A.,PICCIRILLO M.,MINEO E.,CATALANI P.,GRIBALDO L., MARAFANTE E., NERI MG.,RAIMONDI A. Role of SR-4987 stromal cells in the modulation of Doxorubicin toxicity to in vitro granulocyte-macrophage progenitors (GM-CFU). Life Sciences, 65, ,

7 PESSINA A., ROSSONI L.,PICCIRILLO M.,SALA G.,NERI MG.. Preliminary study on in vitro activity and cytotoxicity on cell cultures of a new polyene antifungal molecule (SPA-S-843). Eur. J. Pharmac. Biopharmac. 47, ,1999. GRIBALDO L.,CASATI S.,CASTOLDI A., PESSINA A.Comparison of In Vitro drug sensitivity of Human Granulocyte-Macrophage progenitors from two different origins:umbilical cord blood and bone marrow. Exp. Hematol., 27, ,1999. FULL PAPERS BIGI G.,PESSINA A- Immunità e tumori. Sapere,753,24-29, CLERICI E.,GAROTTA G.,PORTA C.,PESSINA A.,VILLA ML. Immunological aspects of amyloydosis. Isr.J.Med.Sc., 9, ,1973. PORTA C.,PESSINA.A. Complemento e infiammazione. Sapere, 757,28-30,1973. PESSINA A.,BRAMBILLA P.,BALZARIN D. Inhibition of Ehrlich ascites carcinoma (EAC) growth by carbonyl iron. Experientia,34, ,1978. PESSINA A.,BRAMBILLA P.,MOCARELLI P. Surface antigen on Ehrlich Ascites Tumor Cells. Biomedicine.,33, ,1980. PESSINA A.,ERIDANI S., BRAMBILLA P., CATTORETTI G, MAROCCHI A., MOCARELLI P. Effect of tumor related factors on the in vivo and in vitro colony forming ability of normal mouse marrow cells. Neoplasma,28, ,1981 PESSINA A.,BRAMBILLA P.,VILLA S.,MAROCCHI A.,MOCARELLI P.. Factors produced by macrophages and tumor cells: influence on the granulocytic precursor cells(cfu-c) in normal and tumor bearing mice. J.Cancer Res.Clin.Oncol.,102, ,1982. PESSINA A.,BRAMBILLA P.,VILLA S.,MOCARELLI P.. CFU-s and CFU-C proliferation after treatment of normal bone marrow cells with tumoral ascitic fluid. Oncology, 39, ,1982. PESSINA A.,NERI M.G.,MUSCHIATO A..Effect of heat-labile enterotoxin (LT) produced by Escherichia coli on in vitro cell proliferation. Experientia.,38, ,1982. SIRCHIA G.,ROSSO DI SAN SECONDO V.E.M.,TEDESCO F.,FORTIS C.,ALCINI D.,GIOVANETTI A.M.,GUAZZOTTI L.,ZANUSSI C.,SCORZA R.,FABIO G.,BONARA P.,MERONI P.L.,SABBADINI M.G.,VANOLI M., PETTENATI C.,MOCARELLI P.,PESSINA A., BRAMBILLA P.,MAROCCHI A., CAREDDU P.,BARDARE M.,CORONA F.,CHIAPPINO G.,NAVA C.,MEREGALLI G.,GARATTINI S., SPREAFICO F.,VECCHI A.,MANTOVANI A.,MARUBINI E.,MILANI S.. Exposure to TCDD:Immunologic Effects. In:Plans for clinical and epidemiologic follow-up after area-wide chemical contamination. Proc.Int.Workshop,Washington,D.C.,March 1980.Eds.L. Dardanoni, R.W.Miller. Natl.Acad.Press,Washington M arch Pagg PESSINA A.,NERI M.G.,MUSCHIATO A.,RAIMONDI A.. Inhibition of granulocytic-macrophagic precursor cells (CFU-C) by heat-labile enterotoxin (LT) produced by Escherichia coli. Biomed. Pharmacother.37, ,1983. PESSINA A.,NERI M.G.. Factors affecting the proliferation of a murine T-cell lymphoma. Chemioterapia,S5, ,1983. PESSINA A.,BRAMBILLA P.,MOCARELLI P..Modulation of EL-4 mouse lymphoma cell proliferation by macrophages and tumor related factors. Blut 49,45-51,

8 SEZZANO P.,RAIMONDI A.,PESSINA A.,NERI M.G..Isolation and partial chracterization of temperate bacteriophages from enteropathogenic strains of Escherichia coli O111:K58. Acta Virologica,29,73-78,1985. PESSINA A.,BRAMBILLA P.,NERI M.G.,MOCARELLI P..Production of colony stimulating factor by EL-4 lymphoma cells stimulated with phytohemoagglutinin. Int. J. Immunopharmac., 7, ,1985. RAIMONDI S.,DONGHI R.,MONTAGUTI A.,PESSINA A.,DEHO' G..Analysis of spontaneous deletion mutants of satellite bacteriophage P4. J.Virol.,54, ,1985. PESSINA A.,NERI M.G..Colony stimulating factor produced by T-lymphoma cells. Chemioterapia,S2, ,1985. PESSINA A.,NERI M.G.,MUSCHIATO A.,BRAMBILLA P.,MAROCCHI A. MOCARELLI P.. Colony stimulating factor produced by murine adrenocortical tumor cells. J.Natl.Cancer Inst.,76, ,1986. PESSINA A.,MUSCHIATO A.,COLOMBO M.,NERI M.G..Escherichia coli heat-labile enterotoxin:biological activity of crude filtrate and fractions isolated by gel chromatography. Chemioterapia, S2,46-48,1987. NERI M.G.,OTTOLENGHI A.,PESSINA A.,DE CHIARA A., MAGLIANO E..Detection of enterotoxigenic strains of E.coli in children with acute diarrhea. Chemioterapia,S2,44-45,1987. PESSINA A.,MUSCHIATO A.,NERI M.G..Isolation of a colony stimulating factor produced by L1210 murine leukemia cells. Blut.,55, ,1987. PESSINA A.,MATTINA R.,COCUZZA C.E.. Attività biologica dei chinoloni sulle cellule procariote ed eucariote. Farmaci & Terapia,4, ,1987. NERI M.G.,PESSINA A.,OTTOLENGHI A.,COCUZZA G.. Enterobatteri produttori di tossina termolabile nelle diarree acute. L'Igiene Moderna,89, ,1988. PESSINA A.,NERI M.G.,IANNETTA M.,MINEO E.. Effect of fluorinated quinolones on heat-labile toxin production by Escherichia coli. J.Chemother.,S4, ,1989. PESSINA A.,NERI M.G.,MINEO E.,COCUZZA C.E..Effect of quinolones on the production of colony stimulating factors by macrophages. J.Chemother.S4, ,1989. PESSINA A.,NERI M.G.,MUSCHIATO A.,MINEO E.,COCUZZA G..Effect of fluoroquinolones on the in vitro proliferation of myeloid precursor cells. J.Antimicrob. Chemother.,24, ,1989. PESSINA A.. Citochine: quale futuro in campo diagnostico? Diagnosis,1, ,1989. PESSINA A.,MINEO E.,MASSERINI M.,NERI M.G.,COCUZZA C.E.. Inhibition of murine leukemia (WEHI-3B and L1210) proliferation by cholera toxin B subunit. Biochim. Bioph. Acta.1013, ,1989. PESSINA A.,NERI MG.,GRIBALDO L.,MINEO E.,COCUZZA G.. Sensibilità in vitro di cellule leucemiche e precursori mieloidi murini a fluorochinoloni. J.Chemother.,S2, ,1990. PESSINA A.,MINEO E.,NERI M.G.,COCUZZA G..In vitro effect of fluoroquinolones on macrophages response to LPS stimulation and phagocytosis. J.Chemother.,S4, ,1991. PESSINA A.,MINEO E.,GRIBALDO L.,MANCINA G.,NERI MG.. Lack of in vitro antiviral activity of fluoroquinolones against herpes simplex virus type 2. Arch.Virol.,122, ,1992. PESSINA A., MINEO E.,NERI MG.,GRIBALDO L.,COLOMBO R., BRAMBILLA P.,ZALESKIS G.. Establishment and characterization of a new murine cell line (SR-4987) derived from marrow stromal cells. Cytotechnology.,8,93-102,1992. PESSINA A. Dimmi cosa fai e ti dirò chi sei. Editoriale Diagnosis,5,201,

9 PESSINA A.,GRIBALDO L.,MINEO E.,NERI MG.. Effect of fluoroquinolones on the in vitro production of tumor necrosis factor(tnf) by P388D1 cells. J.Chemother.,5, ,1993 PESSINA A.,MINEO E.,GRIBALDO L.,MANCINA G.,NERI MG.,MORAN E.,CLEARY I., CLYNES M. Susceptibility of leukemia cell lines to quinolones and induction of resistance to ciprofloxacin in WEHI-3B(D+) leukemia cells. Cancer J.,6, ,1993. PESSINA A. Topoisomerase I in multiple drug resistance. Cytotechnology, 12, ,1993. PESSINA A.,GRIBALDO L.,MINEO E.,NERI MG.. In vitro short-term and long-term cytotoxicity of fluoroquinolones on murine cell lines. Ind. J. Exp. Biol.,32, ,1994. RAIMONDI A.,PESSINA A., COCUZZA G. Outer membrane permeability of Serratia marcescens to meropenem and imipenem. J.Chemother.6, ,1995. PESSINA A.,RAIMONDI A., NERI MG. Different biological conditions influencing bacterial adherence assay. J.Chemother.,7,8-11,1995 PESSINA A.,ZALESKIS G.,MINEO E.,CERRI A., NERI MG. Expression of CD antigen on SR-4987 murine marrow stromal cells. J.Exp. Clin. Cancer Res. 14, ,1995. NERI M.G.,MINEO E.,PICCIRILLO M., PESSINA A.. Attività microbicida di benzalconio cloruro-alcansolfonato sodico su microorganismi di interesse veterinario. Ingegneria Alimentare, 6,25-29,1995. GIULIANI A.,CALAPPI E., MINEO E.,NERI MG.,MASSERINI M., GALLINA A.,PESSINA A. The different inhibiting effect of cholera toxin on two leukemia cell lines does not correlate with their toxin binding capacity. Mol.Cell.Biochem,152, ,1995 PESSINA A. Coltivatori di cellule in vitro. Kos,119/120,23-25,1995. PESSINA A.,PICCIRILLO M.,MINEO E.,TASSI E.,BRAMBILLA P., NERI MG.. A simple quantitative bioassay for basic fibroblast growth factor using SR-4987 cells as target. Meth. Mol. Cell. Biol.,5, ,1995. RAIMONDI A.,PESSINA A., NERI MG.. Loss of Porins Following Carbapenem-Resistance Selection and Adherence Modification in Enterobacteria. J.Chemother. 7, ,1995. GRIBALDO L.,BUEREN J.,DELDAR A.,HOKLAND P.,MEREDITH C.,MONETA D., MOSESSO P., PARCHMENT R., PARENT-MASSIN D.,PESSINA A., SAN ROMAN J., SCHOETERS G.. The use of in vitro systems for evaluating haematotoxicity. ATLA, 24, ,1996 PESSINA A.,NERI MG.,MINEO E.,PICCIRILLO M.,GRIBALDO L.,BRAMBILLA P.,ZALESKIS G.,UJHAZY P.. Expression of B cell markers on SR-4987 cells derived from murine bone marrow stroma. Exp. Hematol. 25, ,1997. GRIBALDO L.,PICCIRILLO M.,CASATI S.,COLLOTTA A.,MINEO E.,PESSINA A.. Drug sensitivity of granulocyte-macrophage precursors (GM-CFU) from fresh murine bone marrow and from long- term bone marrow cultures. Toxicology In Vitro, 12, 39-45, PESSINA A.,MINEO E.,NERI MG.,PICCIRILLO M.,VALORE L.,GIULIANI A..SR-4987 and L1210 cell lines :two models in which the cholera toxin susceptibility does not correlate with camp accumulationa and ganglioside content. Cell.Mol.Biol.,44, ,1998. PARCHMENT R.E, PESSINA A. Topoisomerase I inhibitors and drug resistance. Cytotechnology, 27, ,1998. PESSINA A.,PICCIRILLO M.,MINEO E.,CATALANI P.,GRIBALçDO L.,MARAFANTE E., NERI MG.,RAIMONDI A. Role of SR-4987 stromal cells in the modulation of Doxorubicin toxicity to in vitro granulocytemacrophage progenitors (GM-CFU). Life Sciences, 65, ,1999. PESSINA A. Appunti di Viaggio. Un ricercatore di fronte ai dati della realtà. Emmeciquadro,10,25-30,

10 PESSINA A., ROSSONI L.,PICCIRILLO M.,SALA G.,NERI MG.. Preliminary study on in vitro activity and cytotoxicity on cell cultures of a new polyene antifungal molecule (SPA-S-843). Eur. J. Pharmac. Biopharmac. 47, ,1999. GRIBALDO L.,CASATI S.,CASTOLDI A., PESSINA A.Comparison of In Vitro drug sensitivity of Human Granulocyte-Macrophage progenitors from two different origins:umbilical cord blood and bone marrow. Exp. Hematol., 27, ,1999. GRIBALDO L, MALERBA I.,COLLOTTA A.,CASTI S.,PESSINA A.. Inhibition of CFGU-e/BFU-E by 3 -azido- 3 - deoxythymidine,chlorpropamide and protoporphirin IX zinc (II): a comparison between direct exposure of progenitor cells and long-term exposure of bone marrow. Toxicological Sciences 58, ,2000. PESSINA A.,RAIMONDI A:;CROERA C:, ACCHINI M:,MINEO E.,FOTI P:,NERI MG:: Altered DNA cleavage activity of topoisomerase II from WEHI-3B leukemia cells resistantto ciprofloxacin. Anti-Cancer Drugs,12, ,2001 PESSINA A,RAIMONDI A.CERRI A. PICCIRILLO M, NERI MG, CROERA C.,FOTI sensitivity of human epidermal keratinocytes (HaCaT) to topoisomerase inhibitors. Cell Proliferation,34, ,2001. P.,BERTI E. High PESSINA A., ALBELLA B., BUEREN J.,.BRANTOM P., CASATI S.,.CROERA C., GAGLIARDI G., GRIBALDO L, FOTI P., PARCHMENT R., PARENT-MASSIN D., SCHOETERS G., SIBIRIL Y.,VAN DEN HEUVEL Prevalidation of a model for predicting acute neutropenia by Colony Forming Unit-Granulocyte/Macrophage CFU-GM) assay Toxicology in Vitro, 15, ,2001. PESSINA A., GIULIANI A., CROERA C., FOTI P., MASCOLO L. GAGLIARDI G. NERI MG. Selection of a WEHI-3B leukemia cell subclone resistant to inhibition by cholera toxin. Mol.Cell Biochem., 233,19-26,2002. PESSINA A., GAGLIARDI G.,CROERA C.FOTI P.,DASSI C.BRAMBILLA P.,NERI MG.. Secretion of basic fibroblast growth factor (FGF-2) by WEHI-3B myelomonocitic leukemia cells. Growth Factors, 20, ,2002. PESSINA A., ALBELLA B., BAYO M., BUEREN J.,.BRANTOM P., CASATI S., CROERA C., PARCHMENT R., PARENT-MASSIN D., SCHOETERS G., SIBIRIL Y.,VAN DEN HEUVEL R.,.GRIBALDO L. In vitro tests for haematotoxicity: Prediction of drug induced Myelosuppression by the CFU-GM assay. ATLA (Altern. Lab. Anim) 30 S2:75-79, RAIMONDI A.,SISTO F.,RIZZARDI R., PESSINA A.,TICOZZI R.,NERI MG.. Sequenza di due forme alleliche del gene di beta-lattamasi cromosomiale di S.marcescens. Effetto della loro espressione sulla sensibilità ad antibioticibetalattamici di ospiti Trasformati GIMNOC,Vol VI:53-56,2002. PESSINA A., ALBELLA B., BAYO M., BUEREN J.,.BRANTOM P., CASATI S.,.CROERA C.,GAGLIARDI G FOTI P, PARCHMENT R., PARENT-MASSIN D.,SCHOETERS G., SIBIRIL Y.,VAN DEN HEUVEL R.,.GRIBALDO L.Application of the CFU-GM assay to predict acute drug-induced neutropenia:an international blind trial to validate a prediction model for the maximum tolerated dose(mtd) of myelosuppressive xenobiotics. Toxicological Sciences, 75, ,2003. ROSEEUW E.,COESSENS V.,BALAZUC AM.,LAGRANDERIE M.,CHAVAROT P.,PESSINA A., NERI MG., SCHACHT E.,MARCHAL G., DOMURADO D..Synthesis, degradation and antimicrobial properties of targeted macromolecular prodrugs ofnorfloxacin. Antimicrob. Agents Chemother.,47, ,2003. PESSINA A., BAYO M.,CROERA C.,MERINGOLO F.,NERI MG.MONTESISSA L.,RAIMONDI A. In vitro sensitivity of Human Gastric Cancer Cells( HGC-27) to Helicobacter pylori cytotoxin. Scand. J. Gastroenterol. 12: ,2003. PESSINA A. Le cellule staminali. Ricerca, problemi applicazioni. Emmeciquadro 17:16-24,2003. PESSINA A.,GIULIANI A.,CROERA C.,GAGLIARDI G.,NERI. MG. Different response to "in vitro" cholera toxin treatment by three murine cell models. L'Igiene Moderna 120: ,

11 PESSINA A., CROERA C., BAYO M., MALERBA I., PASSARDI L., CAVICCHINI L., NERI M.G., GRIBALDO L. A methylcellulose microculture assay for the in vitro assessment of drug toxicity on granulocyte- macrophage progenitors (CFU-GM). ATLA 32:17-23, 2004 PESSINA A.,ELETTI B:,CROERA C.,SAVALLI N.,DIODOVICH C.,GRIBALDO L..Pancreas developing markers expressed on human mononucleated umbilical cord blood cells.biochem Biophys. Res. Comm. 323: ,2004 PESSINA A., MALERBA I., GRIBALDO L. Haematotoxicity testing by cell clonogenic assay in drug development and preclinical trials Curr.Pharmaceut.Design 11: ,2005. PESSINA A.,TURLIZZI E.,BONOMI A. et al. In vitro toxicity of clozapine,olanzapine and quetiapine on granulocytemacrophage progenitors(gm-cfu).pharmacopsychiatry,39,20-22,2006. PESSINA A.,CROERA C.,SAVALLI N. et al. Bcl-2 down modulation in WEHI-3B/CTRES cells resistant to Cholera Toxin (CT)-induced apoptosis. Cell Res. 16: ,2006 PESSINA A. and GRIBALDO L. The key role of adult stem cells: therapeutic perspectives. Opin.,22, ,2006. Curr. Med. Res. PESSINA A.,BONOMI A.CASATI S. et al. Mitochondrial function, apoptosis and cell-cycle delay in the WEHI-3B leukemia cell line and its variant ciprofloxacin-resistant WEHI-3B/CPX. Cell Prolif.,40, ,2007. PESSINA A.,BONOMI A.,BAGLIO C. et al. Microbiological Risk Assessment In Stem Cell Manipulation. Crit.Rev.Microbiol, 34:1-12,2008. PESSINA A.,PARENT-MASSIN D., ALBELLA B.et al. Application of human CFU-Mk assay to predict potential thrombocytotoxicity of drugs. Toxicology in Vitro, 23: ,2009. PESSINA A.,BONOMI A.,BAGLIO C.,CAVICCHINI L.,GRIBALDO Refinement and optimisation of the rat CFU- GM assay to use cryopreserved bone marrow cells for in vitro toxicology application. Altern.To Lab.Animals (ATLA) 37: ,2009. PESSINA A.,BONOMI A.,COCCÈ V. et al. Assessment of human herpesvirus-6 infection in cells ex vivo expanded for clinical use.transpl Infect Dis T.11 : ,2009. mesenchymal stromal PESSINA A.,BONOMI A.,CAVICCHINI L. et al. Prevalidation of Rat GM-CFU Assay for In Vitro Toxicology Application. Altern.To Lab.Animals (ATLA) 38: ,2010. PESSINA A., BONOMI A.,SISTO F. er al. CD45+/CD133+ positive cells expanded from umbilical cord blood expressing pdx-1 and markers of pluripotency. Cell Biol. Int.34: ,2010. PESSINA A. Cellule staminali pluripotenti. Le prospettive delle ipsc restano problematiche. Emmeciquadro 38: 27-30,2010. LULLI M, DI GESUALDO F.,WITORT E.,PESSINA A.,CAPACCIOLI S. Cell death: physiopathological and therapeutic implications. Cell Death Dis. 1: e30; doi: /cddis PESSINA A.,SISTO F.,COCCE V. et al. A mesenchymal stromal cell line resistant to paclitaxel that spontaneously differentiates into Osteoblast-like cells. Cell Biol Toxicol 27: ,2011. PESSINA A., BONOMI A., COCCE V. et al. Mesenchimal stromal cells primed with paclitaxel provide a new approach for cancer therapy. PloSONE, 6, Issue 12, e28321,2011. PESSINA A, COCCÈ V,.BONOMI A.,CAVICCHINI L., SISTO F., FERRARI M., NAVONE S., MARFIA G., PARATI E., ALESSANDRI G. Human Skin-Derived Fibroblasts Acquire In Vitro Anti-Tumor Potential after Priming with Paclitaxel. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13,

12 PESSINA A, COCCÈ V,. PASCUCCI L.,BONOMI A.,CAVICCHINI L., SISTO F., FERRARI M.,CIUSANI E.,NAVONE S., MARFIA G., BENETTI A. CECCARELLI P.,PARATI E., ALESSANDRI G. Mesenchymal stromal cells primed with Paclitaxel attract and kill leukemia cells, inhibit angiogenesis and improve survival of leukemiabearing mice. British Journal of Haematology, 2013, 160, BONOMI A., COCCÈ V,.CAVICCHINI L., SISTO F., DOSSENA M.,BALZARINI P. PORTOLIANI N.,CIUSANI E.,PARATI E., ALESSANDRI G. PESSINA A. Adipose-tissue-derived stromal cells primed in vitro with paclitaxel acquires anti-tumor activity. Int. J.Immunopath. Pharmacol. 2013,26, L.DE GIROLAMO, E.LUCARELLI, G. ALESSANDRI, M.A. AVANZINI, M.E. BERNARDO, E.BIAGI, A.T.BRINI, G.D AMICO, F.FAGIOLI, I.FERRERO, F.LOCATELLI, R.MACCARIO, M.MARAZZI, O.PAROLINI, A. PESSINA*,M.L.TORRE * Italian Mesenchymal Stem Cell Group (GISM). Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm. Efficacy and Critical Aspects in Cell Therapy.Curr. Pharmaceut. Des. 2013,19, CHAPTERS OF BOOKS CLERICI E.,GAROTTA G.,PORTA C.,BIGI G.,PESSINA A. Reattività immunologica nel feto e nel neonato. In: Corso di perfezionamento in metodiche immunologiche e Simposio sui problemi di immunologia di interesse pediatrico. Ed. Piccin,Padova. Pagg ,1977. CLERICI E.,PORTA C.,BIGI G.,GAROTTA G.,PESSINA A. Tecniche per la quantizzazione delle cellule staminali dei B e T linfociti e metodi di studio dell'anticorpopoiesi "in vitro".in: Corso di perfezionamento in metodiche immunologiche e Simposio sui problemi di immunologia di interesse pediatrico. Ed. Piccin,Padova. Pagg ,1977. PESSINA A. I colony stimulating factors: regolatori della proliferazione e della differenziazione dei precursori granulo- macrofagico. Dispensa per la "Scuola di Specializzazione in Farmacologia ",Facolta di Farmacia,1983. PESSINA A.,MUSCHIATO A.,NERI M.G.. Isolation of colony stimulating factors produced in vitro by murine adrenal tumor cells. In : Biological Regulation of Cell Proliferation. Baserga R.,Foa P.,Metcalf D.,Polli E.E.,Eds. Raven Press,New York,1986. Vol. 34,pagg PESSINA A.. The Granulocyte/Macrophage Colony Forming Unit Assy. In:Animal Cell Culture Techniques. Ed.M. Clynes,pp ,Springer-Verlag,, Heidelberg 1998 PESSINA A., ALBELLA B., BUEREN J.,.BRANTOM P., CASATI S., CORRAO G., GRIBALDO L., PARCHMENT R.,PARENT-MASSIN D.,PICCIRILLO M.,RIO B.,SACCHI S.,SCHOETERS G.,Van Den HEUVEL R.. Method developement for a prevalidation study of in vitro GM-CFU assay for predicting myelotoxicity.. In: Progress in the reduction, refinement and replacement of animal experimentation. Balls M,van Zeller A-M, Halder M (eds). Amsterdam: Elsevier, 2000 Pages PESSINA A.,BONOMI A. CFU-GM assay for evaluation of drug Myelotoxic Activity Curr.Prot.Toxicol. 34: , Eds. John Wiley & Sons,Inc., PESSINA A.,BONOMI A. Prediction of potential drug myelotoxicity by in vitro assays on haematopoietic progenitors. In Methods in Bioengineering Tim Maguire and Eric Novik Eds, Artech House Boston-London. Pages ,2010. PESSINA A,.BONOMI A., PARATI E., PALLINI R., ALESSANDRI G. Primed mesenchymal stromal cells for cancer therapy. In Stem Cell Therapeutics for Cancer. Ed Khalid Shah. John Wiley & Sons, Inc., USA.( 2013, In Press) PESSINA A., BONOMI A., CIUSANI E., PASCUCCI L.,PARATI E., ALESSANDRI G. Paclitaxel: Biosynthesis, Mechanisms of Action and Clinical Uses''in Mesenchymal stromal cells used for carrying and delivering Paclitaxel NOVA SCIENCE PUBLISHERS,INC.Hauppauge, NY , USA ( 2013 in press) ACTA, PROCEEDINGS AND EXTENDED ABSTRACTS 12

13 MOCARELLI P.,VILLA ML.,PESSINA A.,BIGI G.,CLERICI E. Meccanismi cellulari della immunodepressione da tumore.rendiconti Acc. Naz. Lincei,XLIX, ,1970. PESSINA A.,PORTA C.Lymphoid repopulation and immune response in X-irradiated mice. Atti Simposio Internaz.Ematologia. Ed.Viscontea, Milano.pagg. 5-12,1975. ERIDANI S.,PESSINA A.,BRAMBILLA P.,PERRONE G.,MOCARELLI P. Influenza di fattori di origine neoplastica sulla ripopolazione esogena di CFU-s nel topo. In: Lo studio delle cellule staminali in vitro. Ed.M.A.Brunelli et al.,esculapio,bologna. Pag ,1976. SEZZANO P.,RAIMONDI A.,GHIDONI G.,PESSINA A.,NERI MG..Caratteristiche di batteriofagi temperati isolati da E.coli enteropatogeni di differenti sierogruppi. Atti XX ongr.naz.microbiologia..brescia-gardone, Maggio Pagg SEZZANO P.,RAIMONDI A.,PESSINA A.,NERI MG.. Fattori di patogenicita e lisogenia in E.coli O111:K58.Atti XX Congr.Naz. Microbiologia..Brescia-Gardone, Maggio 1983.Pagg RAIMONDI A.,SEZZANO P.,PESSINA A.,DONGHI R.,DEHO' G.. Isolamento e caratterizzazione di mutanti delezione del batteriofago satellite P4. Atti XX Congr.Naz.Microbiologia..Brescia-Gardone, Maggio Pagg PESSINA A.,BRAMBILLA P.,MOCARELLI P.,NERI MG.. Conditioned media from tumoral and transformed cell cultures:biological acttivity on stem cell differentiation. Proc.13th Int.Congress Chemother.,K.H.Spitzy and K.Karrer Eds.,,Vienna Settembre1983. PESSINA A.,MUSCHIATO A.,NERI M.G.. Production of colony stimulating factors by L1210 leukemia cells. In:"In vitro control of cell differentiation",ed.rizzoli C.,Bologna,1985. Pag.18. PESSINA A.,MUSCHIATO A.,NERI M.G.. Modulazione dell'attività di colony stimulating factors da parte di tossina termolabile di E.coli. Atti XXI Congr.Naz.Soc.It.Microbiologia,Roma,Dicembre Pag.439. RONDININI G.,PESSINA A.,NERI M.G.,OTTOGALLI G.. Ricerca di enterobatteri produttori di tossina termolabile in prodotti lattiero-caseario. Atti XXI Congr.Naz.Soc.It.Microbiologia,Roma Dicembre Pag.549. PESSINA A.,MUSCHIATO A.,NERI M.G.. Isolation of colony stimulating factors produced in vitro by murine adrenal tumor cells. Commun. to the "Int.Symposium on Biological Regulation of cell proliferation.milan, Marzo, Pag.115. MOCARELLI P.,BRAMBILLA P.,MAROCCHI A.,PESSINA A.,COLOMBO L.,TRAMACERE P.L.,SARTO C.. Purification of GM-CSF from the myoepithelioma cell line SGC-A. Commun. to the "Int. Symposium on Biological Regulation of cell proliferation. Milano Marzo,1986.Pag.87. PESSINA A.,NERI M.G.,MUSCHIATO A.,COCUZZA G.. Effetto della pefloxacina sulla proliferazione di precursori mieloidi. Atti XV Congr.Naz. Soc. It.Chemioterapia. Pesaro-Urbino Giugno Ed.CIC srl,roma.pag PESSINA A.,NERI M.G.,MINEO E.,COCUZZA G.. Effect of lomefloxacin (LMFX) and ciprofloxacin(cpfx) on the in vitro proliferation of granulocyte-macrophage precursors. Proc. 16th Int.Congr.Chemother.,Jerusalem June 1989.Pag PESSINA A.,MINEO E.,GRIBALDO L.,NERI MG. Cytotoxicity of fluoroquinolones on murine cell lines. Proc."5th Int. Symposum on Clinical and Environmental Microbiology", Brescia,October 1991.Pagg ABSTRACTS AND COMMUNICATIONS TO CONGRESS ( about 100 not reported ) 13

Drug Development Services

Drug Development Services Drug Development Services USING BLOOD AND BONE MARROW PRIMARY CELL SYSTEMS Clinically Relevant In Vitro Assays Broad Spectrum of Drug Classes Multi-Species Platforms Enhancing Drug Development through

More information

Ariela Benigni. Biol.Sci.D., Ph.D. Curriculum Vitae

Ariela Benigni. Biol.Sci.D., Ph.D. Curriculum Vitae Ariela Benigni Biol.Sci.D., Ph.D. Curriculum Vitae Personal Data Name: Date and place of birth: Citizenship: E-mail: Ariela Benigni December 16, 1955 - Bergamo, Italy Italian ariela.benigni@marionegri.it

More information

Curriculum Vitae of Luca Gianni

Curriculum Vitae of Luca Gianni Education: 1976: State University of Milan, Milan, Italy: Medical Doctor with honors 1981: State University of Milan, Milan, Italy: Board- Certified in Internal Medicine Brief Chronology of Activities

More information

The haematotoxic potential of xenobiotics is determined by the evaluation of the inhibition of CFU-GM growth.

The haematotoxic potential of xenobiotics is determined by the evaluation of the inhibition of CFU-GM growth. Colony Forming Unit-Granulocyte/Macrophage (CFU-GM) Assay DB-ALM Protocol n 101 Haematotoxicity, Systemic Toxicity The haematotoxic potential of xenobiotics is determined by the evaluation of the inhibition

More information

Future Oncology: Technology, Products, Market and Service Opportunities

Future Oncology: Technology, Products, Market and Service Opportunities Brochure More information from http://www.researchandmarkets.com/reports/296370/ Future Oncology: Technology, Products, Market and Service Opportunities Description: Future Oncology is an analytical newsletter

More information

Fee-for-service cores for Investigational New Drug enabling studies

Fee-for-service cores for Investigational New Drug enabling studies UC DAVIS INSTITUTE FOR REGENERATIVE CURES Fee-for-service cores for Investigational New Drug enabling studies Pipeline pathway at UC Davis Institute for Regenerative Cures Basic Research Proof of Concept

More information

Basic Overview of Preclinical Toxicology Animal Models

Basic Overview of Preclinical Toxicology Animal Models Basic Overview of Preclinical Toxicology Animal Models Charles D. Hebert, Ph.D., D.A.B.T. December 5, 2013 Outline Background In Vitro Toxicology In Vivo Toxicology Animal Models What is Toxicology? Background

More information

Curriculum Vitae. Education. Brief Chronology of Employment. Academic Positions held. Pier Paolo Di Fiore M.D. Ph.D.

Curriculum Vitae. Education. Brief Chronology of Employment. Academic Positions held. Pier Paolo Di Fiore M.D. Ph.D. Pier Paolo Di Fiore M.D. Ph.D. Curriculum Vitae Education 1981 - M.D., summa cum laude, University of Naples, 2nd Medical School, Naples, Italy 1984 - Board in Oncology, summa cum laude, University of

More information

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational

More information

CONTENT. Chapter 1 Review of Literature. List of figures. List of tables

CONTENT. Chapter 1 Review of Literature. List of figures. List of tables Abstract Abbreviations List of figures CONTENT I-VI VII-VIII IX-XII List of tables XIII Chapter 1 Review of Literature 1. Vaccination against intracellular pathogens 1-34 1.1 Role of different immune responses

More information

Purification and Expansion of Hematopoietic Stem Cells Based on Proteins Expressed by a Novel Stromal Cell Population

Purification and Expansion of Hematopoietic Stem Cells Based on Proteins Expressed by a Novel Stromal Cell Population Purification and Expansion of Hematopoietic Stem Cells Based on Proteins Expressed by a Novel Stromal Cell Population Our bodies are constantly killing old, nonfunctional, and unneeded cells and making

More information

A Genetic Analysis of Rheumatoid Arthritis

A Genetic Analysis of Rheumatoid Arthritis A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.

More information

JUMISC JUMISC. For further information visit our website:

JUMISC JUMISC. For further information visit our website: STEM CELL THERAPY COMPANY PROFILE & SCIENTIFIC ACTIVITIES For further information visit our website: WWW.CCMIJESUSUSON.COM 20 14 JUMISC JUMISC Carretera N-521, km. 41,8 10071 CÁCERES (SPAIN) Tel. (+34)

More information

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes

More information

Biotechnology. Srivatsan Kidambi, Ph.D.

Biotechnology. Srivatsan Kidambi, Ph.D. Stem Stem Cell Cell Engineering-What, Biology and it Application Why, How?? to Biotechnology Srivatsan Kidambi, Ph.D. Assistant Professor Department of Chemical & Biomolecular Engineering University of

More information

Stem Cell Quick Guide: Stem Cell Basics

Stem Cell Quick Guide: Stem Cell Basics Stem Cell Quick Guide: Stem Cell Basics What is a Stem Cell? Stem cells are the starting point from which the rest of the body grows. The adult human body is made up of hundreds of millions of different

More information

Do you have anything to add? If so, I d love to hear from you! Jessica Robinson Conference Manager Life Sciences @jessbiopharma

Do you have anything to add? If so, I d love to hear from you! Jessica Robinson Conference Manager Life Sciences @jessbiopharma 1 Who is the most influential figure in cord blood around the world? What is the biggest challenge to overcome in the use of cord blood as a source of stem cells? We asked 10 leading experts in the cord

More information

Evaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia

Evaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia Evaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia Dr Jordi Sierra Gil IRHSP Institut de Recerca Hospital de la Santa Creu i Sant Pau Dr. Miguel Ángel Sanz Alonso Fundación

More information

Micromyx. Micromyx. A Microbiology Services Company. Lab Services Research - Consulting -

Micromyx. Micromyx. A Microbiology Services Company. Lab Services Research - Consulting - A Microbiology Services Company Lab Services Research - Consulting - Regulatory Company description is a microbiology services company specializing in antiinfective discovery and development for the pharmaceutical,

More information

GRANIX (tbo-filgrastim)

GRANIX (tbo-filgrastim) RATIONALE FOR INCLUSION IN PA PROGRAM Background Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils. A person with severe neutropenia has an absolute neutrophil

More information

MULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist

MULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist MULTIPLE MYELOMA Dr Malkit S Riyat MBChB, FRCPath(UK) Consultant Haematologist Multiple myeloma is an incurable malignancy that arises from postgerminal centre, somatically hypermutated B cells.

More information

Farmacologia degli inibitori TK e mtor

Farmacologia degli inibitori TK e mtor Farmacologia degli inibitori TK e mtor Romano Danesi Professore ordinario di Farmacologia UOC Farmacologia Universitaria Azienda Ospedaliero-Universitaria Pisana Dipartimento di Medicina Interna Università

More information

Stem cells possess 2 main characteristics: Sources of pluripotent stem cells: -Long-term self renewal. -The inner cell mass of the blastocyst.

Stem cells possess 2 main characteristics: Sources of pluripotent stem cells: -Long-term self renewal. -The inner cell mass of the blastocyst. Stem cells possess 2 main characteristics: -Long-term self renewal. - They give rise to all types of differentiate cells. Sources of pluripotent stem cells: -The inner cell mass of the blastocyst. - Fetal

More information

MAB Solut. MABSolys Génopole Campus 1 5 rue Henri Desbruères 91030 Evry Cedex. www.mabsolut.com. is involved at each stage of your project

MAB Solut. MABSolys Génopole Campus 1 5 rue Henri Desbruères 91030 Evry Cedex. www.mabsolut.com. is involved at each stage of your project Mabsolus-2015-UK:Mise en page 1 03/07/15 14:13 Page1 Services provider Department of MABSolys from conception to validation MAB Solut is involved at each stage of your project Creation of antibodies Production

More information

guides BIOLOGY OF AGING STEM CELLS An introduction to aging science brought to you by the American Federation for Aging Research

guides BIOLOGY OF AGING STEM CELLS An introduction to aging science brought to you by the American Federation for Aging Research infoaging guides BIOLOGY OF AGING STEM CELLS An introduction to aging science brought to you by the American Federation for Aging Research WHAT ARE STEM CELLS? Stem cells are cells that, in cell cultures

More information

FAK INHIBITOR DEFACTINIB (VS-6063) TARGETS MESOTHELIOMA CANCER STEM CELLS. Jonathan Pachter, Ph.D.

FAK INHIBITOR DEFACTINIB (VS-6063) TARGETS MESOTHELIOMA CANCER STEM CELLS. Jonathan Pachter, Ph.D. FAK INHIBITOR DEFACTINIB (VS-6063) TARGETS MESOTHELIOMA CANCER STEM CELLS Rationale for maintenance therapy after conventional therapy Jonathan Pachter, Ph.D. Vice President of Research, Verastem, Inc.

More information

STEM CELL FELLOWSHIP

STEM CELL FELLOWSHIP Module I: The Basic Principles of Stem Cells 1. Basics of Stem Cells a. Understanding the development of embryonic stem cells i. Embryonic stem cells ii. Embryonic germ cells iii. Differentiated stem cell

More information

The role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015

The role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015 The role of IBV proteins in protection: cellular immune responses COST meeting WG2 + WG3 Budapest, Hungary, 2015 1 Presentation include: Laboratory results Literature summary Role of T cells in response

More information

Nuevas tecnologías basadas en biomarcadores para oncología

Nuevas tecnologías basadas en biomarcadores para oncología Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS

More information

The Need for a PARP in vivo Pharmacodynamic Assay

The Need for a PARP in vivo Pharmacodynamic Assay The Need for a PARP in vivo Pharmacodynamic Assay Jay George, Ph.D., Chief Scientific Officer, Trevigen, Inc., Gaithersburg, MD For further infomation, please contact: William Booth, Ph.D. Tel: +44 (0)1235

More information

AAGPs TM Anti-Aging Glyco Peptides. Enhancing Cell, Tissue and Organ Integrity Molecular and biological attributes of lead AAGP molecule

AAGPs TM Anti-Aging Glyco Peptides. Enhancing Cell, Tissue and Organ Integrity Molecular and biological attributes of lead AAGP molecule AAGPs TM Anti-Aging Glyco Peptides Enhancing Cell, Tissue and Organ Integrity Molecular and biological attributes of lead AAGP molecule 1 Acknowledgements This presentation was prepared by Dr. Samer Hussein

More information

Notch 1 -dependent regulation of cell fate in colorectal cancer

Notch 1 -dependent regulation of cell fate in colorectal cancer Notch 1 -dependent regulation of cell fate in colorectal cancer Referees: PD Dr. Tobias Dick Prof. Dr. Wilfried Roth http://d-nb.info/1057851272 CONTENTS Summary 1 Zusammenfassung 2 1 INTRODUCTION 3 1.1

More information

Griffith University - Case for Support. Mesothelioma Research Program

Griffith University - Case for Support. Mesothelioma Research Program Griffith University - Case for Support Mesothelioma Research Program Professor Lyn Griffiths Director, Dean, Research and Director, Genomics Research Centre (GHI) Established in 2007. Integrated health

More information

Roche Position on Human Stem Cells

Roche Position on Human Stem Cells Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with

More information

MATHEMATICAL MODELS OF TUMOR GROWTH INHIBITION IN XENOGRAFT MICE AFTER ADMINISTRATION OF ANTICANCER AGENTS GIVEN IN COMBINATION

MATHEMATICAL MODELS OF TUMOR GROWTH INHIBITION IN XENOGRAFT MICE AFTER ADMINISTRATION OF ANTICANCER AGENTS GIVEN IN COMBINATION MATHEMATICAL MODELS OF TUMOR GROWTH INHIBITION IN XENOGRAFT MICE AFTER ADMINISTRATION OF ANTICANCER AGENTS GIVEN IN COMBINATION Nadia Terranova UNIVERSITÀ DI PAVIA New model development: course of action

More information

Basic Science in Medicine

Basic Science in Medicine Medical Journal of th e Islamic Republic of Iran Volume 18 Number 3 Fall 1383 November 2004 Basic Science in Medicine ] EXPANSION OF HUMAN CORD BLOOD PRIMITIVE PROGENITORS IN SERUM-FREE MEDIA USING HUMAN

More information

Cytotoxic and Biotherapies Credentialing Programme Module 2

Cytotoxic and Biotherapies Credentialing Programme Module 2 Cytotoxic and Biotherapies Credentialing Programme Module 2 1. The Cell Cycle 2. Cancer Therapies 3. Adjunctive Therapies On completion of this module the RN will State the difference between a normal

More information

Disclosure. Gene Therapy. Transfer of genes into cells Expression of transferred genes

Disclosure. Gene Therapy. Transfer of genes into cells Expression of transferred genes Disclosure Equity interest in Genetix Pharm. Inc. Exclusive license of retroviral cell lines from Columbia No direct participation in MDR clinical trials Columbia U. annual reporting FDA Gene Therapy Transfer

More information

30 Nature Methods 31 Nature Microbiology 32 Nature Nanotechnology 33 Nature Neuroscience 34 Nature Photonics 35 Nature Physics 36 Nature Plants 37

30 Nature Methods 31 Nature Microbiology 32 Nature Nanotechnology 33 Nature Neuroscience 34 Nature Photonics 35 Nature Physics 36 Nature Plants 37 Nature titles Journal 1 Nature 2 Nature Reviews Cancer 3 Nature Reviews Cardiology 4 Nature Reviews Clinical Oncology 5 Nature Reviews Disease Primers 6 Nature Reviews Drug Discovery 7 Nature Reviews Endocrinology

More information

Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine

Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine January 27, 2009 Dear Professors (representative) of departments, Subject:

More information

CURRICULUM VITAE ROBERTO GIACOMELLI MD, PhD

CURRICULUM VITAE ROBERTO GIACOMELLI MD, PhD CURRICULUM VITAE ROBERTO GIACOMELLI MD, PhD NAME Roberto Giacomelli TITLE Full Professor of Rheumatology, University of L Aquila, School of Medicine, L Aquila, Italy NATIONALITY Italian ADDRESS Permanent:

More information

Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center

Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center Bodnar s Law Simple Things are Important Very Simple Things are Very Important

More information

ANATOMY OF THE IMMUNE SYSTEM THE IMMUNE SYSTEM. ANATOMY OF THE IMMUNE SYSTEM Thymus glandular organ near the heart where T cells learn their jobs

ANATOMY OF THE IMMUNE SYSTEM THE IMMUNE SYSTEM. ANATOMY OF THE IMMUNE SYSTEM Thymus glandular organ near the heart where T cells learn their jobs THE IMMUNE SYSTEM 1 ANATOMY OF THE IMMUNE SYSTEM 2 We all get sick sometimes...but then we get better. What happens when we get sick? Why do we get better? The immune system is localized in several parts

More information

5 Frequently Asked Questions About Adult Stem Cell Research

5 Frequently Asked Questions About Adult Stem Cell Research 5 Frequently Asked Questions About Adult Stem Cell Research Stem cells are often referred to in the sociopolitical realm with some level of controversy and beyond that, some level of confusion. Many researchers

More information

Activation and effector functions of HMI

Activation and effector functions of HMI Activation and effector functions of HMI Hathairat Thananchai, DPhil Department of Microbiology Faculty of Medicine Chiang Mai University 25 August 2015 ว ตถ ประสงค หล งจากช วโมงบรรยายน แล วน กศ กษาสามารถ

More information

The Therapeutic Potential of Human Umbilical Cord Blood Transplantation for Neonatal Hypoxic-Ischemic Brain Injury and Ischemic Stroke

The Therapeutic Potential of Human Umbilical Cord Blood Transplantation for Neonatal Hypoxic-Ischemic Brain Injury and Ischemic Stroke The Therapeutic Potential of Human Umbilical Cord Blood Transplantation for Neonatal Hypoxic-Ischemic Brain Injury and Ischemic Stroke a,b* b,c a a b b b b a b a b c 430 Wang et al. Acta Med. Okayama Vol.

More information

Newborn Stem Cells from Cord Blood and the Brain: Repairing Injury and Improving Function

Newborn Stem Cells from Cord Blood and the Brain: Repairing Injury and Improving Function BACKROUNDER: Newborn Stem Cells from Cord Blood and the Brain: Repairing Injury and Improving Function Introduction WITH ONGOING DEVELOPMENTS IN RESEARCH, it is estimated that 1 in every 3 people may benefit

More information

Immuno-Oncology Model Application in the Preclinical Treatment Setting

Immuno-Oncology Model Application in the Preclinical Treatment Setting Immuno-Oncology Model Application in the Preclinical Treatment Setting Maryland Franklin, Ph.D. Senior Director, Scientific Development mfranklin@molecularimaging.com July 22, 2015 Tumor Models Conference

More information

FGF-1 as Cosmetic Supplement

FGF-1 as Cosmetic Supplement FGF-1 as Cosmetic Supplement Ing-Ming Chiu, Ph.D. Professor, Internal Medicine and Molecular and Cellular Biochemistry The Ohio State University Columbus, Ohio, U.S.A. GENTEON USA Fibroblast Growth Factor

More information

Additional file 1. Progress of phase II clinical trials of Panagen

Additional file 1. Progress of phase II clinical trials of Panagen Additional file 1. Progress of phase II clinical trials of Panagen Documentation Phase II clinical trial of preparation Panagen was performed in compliance with the following documentation: Approval of

More information

Session 6 Clinical Trial Assessment Phase I Clinical Trial

Session 6 Clinical Trial Assessment Phase I Clinical Trial L1 Session 6 Clinical Trial Assessment Phase I Clinical Trial Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office

More information

Saving Your Baby s Cord Blood

Saving Your Baby s Cord Blood Saving Your Baby s Cord Blood An Important Pregnancy Decision 1-888-CORD BLOOD HEALTHY FUTURES ARE Born at CBR For every parent who wishes they could do more to protect their family s health, there s Cord

More information

Non-clinical development of biologics

Non-clinical development of biologics Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service

More information

Date and place of birth 28th January 1958; Moretta (Cuneo) (Italy). Two children

Date and place of birth 28th January 1958; Moretta (Cuneo) (Italy). Two children ANNA SAPINO Date and place of birth 28th January 1958; Moretta (Cuneo) (Italy). Two children MEDICAL EDUCATION: Medical Degree, University of Turin (1982); Professional specialization in Pathological Anatomy

More information

STEM CELL FACTS. The ISSCR is an independent, nonproft organization providing a global forum for stem cell research and regenerative medicine.

STEM CELL FACTS. The ISSCR is an independent, nonproft organization providing a global forum for stem cell research and regenerative medicine. STEM CELL FACTS The ISSCR is an independent, nonproft organization providing a global forum for stem cell research and regenerative medicine. WHAT ARE STEM CELLS? Stem cells are the foundation cells for

More information

The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor

The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor The immune system Basophil Neutrophil Bone marrow Eosinophil Myeloid progenitor Dendritic cell Pluripotent Stem cell Lymphoid progenitor Platelets Bone marrow Thymus NK cell T-cell B-cell Spleen Cancer

More information

MDM. Metabolic Drift Mutations - Attenuation Technology

MDM. Metabolic Drift Mutations - Attenuation Technology MDM Metabolic Drift Mutations - Attenuation Technology Seite 2 Origin of MDM attenuation technology Prof. Dr. Klaus Linde Pioneer in R&D of human and animal vaccines University of Leipzig Germany Origin

More information

Stem Cells and Inner Ear Cell Regeneration. Stefan Heller Stanford University School of Medicine

Stem Cells and Inner Ear Cell Regeneration. Stefan Heller Stanford University School of Medicine Stem Cells and Inner Ear Cell Regeneration Stefan Heller Stanford University School of Medicine Embryonic stem cells Induced pluripotent stem cells Somatic stem cells 50 µm Derived from the inner cell

More information

Stem cells for brain cures

Stem cells for brain cures 13-14/11/2006, Istituto Superiore di Sanità Rome, Italy Frontiers in Imaging Science: High Performance Nuclear Medicine Imagers for Vascular Disease Imaging (Brain and Heart) Stem cells for brain cures

More information

Course Descriptions. I. Professional Courses: MSEG 7216: Introduction to Infectious Diseases (Medical Students)

Course Descriptions. I. Professional Courses: MSEG 7216: Introduction to Infectious Diseases (Medical Students) Course Descriptions I. Professional Courses: MSEG 7216: Introduction to Infectious Diseases (Medical Students) This course is offered during the first semester of the second year of the MD Program. It

More information

Future Health Technologies. From Academia to Industry The Stem Cell Challenge. Roger J. Dainty MBE FIScT UK Managing Director

Future Health Technologies. From Academia to Industry The Stem Cell Challenge. Roger J. Dainty MBE FIScT UK Managing Director Future Health Technologies From Academia to Industry The Stem Cell Challenge Roger J. Dainty MBE FIScT UK Managing Director How Did I Get Here? Working as a Research Medical Technician (Birmingham University

More information

This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking

This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking Q1/2016 This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking statements involve risks and uncertainties

More information

FACULTY OF ALLIED HEALTH SCIENCES

FACULTY OF ALLIED HEALTH SCIENCES FACULTY OF ALLIED HEALTH SCIENCES 102 Naresuan University FACULTY OF ALLIED HEALTH SCIENCES has focused on providing strong professional programs, including Medical established as one of the leading institutes

More information

Complex Systems BioMedicine: Molecules, Signals, Networks, Diseases

Complex Systems BioMedicine: Molecules, Signals, Networks, Diseases The International School of Advanced Molecular BioMedicine Complex Systems BioMedicine: Molecules, Signals, Networks, Diseases AciTrezza (Catania), Italy, October 2nd-6th, 2009 Hieronymus Bosch: Garden

More information

Human Umbilical Cord-derived Multipotent Mesenchymal Stromal Cells (huc-msc) Handling Instructions

Human Umbilical Cord-derived Multipotent Mesenchymal Stromal Cells (huc-msc) Handling Instructions Human Umbilical Cord-derived Multipotent Mesenchymal Stromal Cells (huc-msc) Order No.: 19401-005, 19401-010 Handling Instructions For preclinical ex vivo use. Not intended for therapeutic use. Table of

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

LESSON 3.5 WORKBOOK. How do cancer cells evolve? Workbook Lesson 3.5

LESSON 3.5 WORKBOOK. How do cancer cells evolve? Workbook Lesson 3.5 LESSON 3.5 WORKBOOK How do cancer cells evolve? In this unit we have learned how normal cells can be transformed so that they stop behaving as part of a tissue community and become unresponsive to regulation.

More information

Curriculum Vitae. Education: Research Associate (Sept. 2009- Current)

Curriculum Vitae. Education: Research Associate (Sept. 2009- Current) Curriculum Vitae Pramod Kumar Giri, Ph.D Research Associate, Department of Microbiology & Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611 USA. Phone: Lab : 001-312-503-1093

More information

Curriculum Vitae - Sara Gandini

Curriculum Vitae - Sara Gandini Curriculum Vitae - Sara Gandini Academic information 2004 PHD IN CANCER STUDIES at the University of Birmingham (Public Health), UK. Thesis: Meta-Analysis in Cancer Epidemiology. 1995 MASTER OF SCIENCE

More information

La Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi

La Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi La Chemioterapia Adiuvante Dose-Dense Lo studio GIM 2 Alessandra Fabi San Antonio Breast Cancer Symposium -December 10-14, 2013 GIM 2 study Epirubicin and Cyclophosphamide (EC) followed by Paclitaxel (T)

More information

Publikationsliste Claudia Götz

Publikationsliste Claudia Götz Publikationsliste Claudia Götz 1. Reinhard,B., Götz, C., and Faillard, H.: Synthesis of N-Acetyl-9-Oacetylneuraminic acid α-p-aminophenylthioketoside and its application as ligand in the affinity chromatography

More information

An Overview of Cells and Cell Research

An Overview of Cells and Cell Research An Overview of Cells and Cell Research 1 An Overview of Cells and Cell Research Chapter Outline Model Species and Cell types Cell components Tools of Cell Biology Model Species E. Coli: simplest organism

More information

Scientific Programme

Scientific Programme Scientific Programme Scientific Committee Hilary Calvert UCL Cancer Institute, London, UK Luca Gianni Ospedale San Raffaele IRCCS, Milan, Italy Ana Maria Gonzalez-Angulo Cristiana Sessa Istituto Oncologico

More information

Luca Romagnoli, Ph.D. Business Development Manager

Luca Romagnoli, Ph.D. Business Development Manager Modelli innovativi di produzione per lo sviluppo di un processo altamente qualitativo di farmaci biologici Luca Romagnoli, Ph.D. Business Development Manager BIOLOGICAL DRUGS - SOURCES Monoclonal antibodies

More information

Equine Stem Cells. Sources, Processing, Expansion, Storage and Shipping

Equine Stem Cells. Sources, Processing, Expansion, Storage and Shipping Equine Stem Cells Sources, Processing, Expansion, Storage and Shipping Sean Owens, DVM, Diplomate ACVP Medical Director, UC Davis Veterinary Regenerative Medicine Laboratory What is a Stem Cell and What

More information

Support structure for genetic material

Support structure for genetic material Support structure for genetic material 1 Making proteins in the RER Making copies of humans 2 Making copies of cells Making copies of genetic material 3 Making copies of genetic material Making copies

More information

Stem cells and motor neurone disease

Stem cells and motor neurone disease Stem cells and motor neurone disease F Stem cell research has fuelled hope of a treatment for a variety of conditions. This information sheet explains what these cells are and includes details of the current

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 23 July 1998 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL

More information

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction

More information

Immuno-Oncology Therapies to Treat Lung Cancer

Immuno-Oncology Therapies to Treat Lung Cancer Immuno-Oncology Therapies to Treat Lung Cancer What you need to know ONCHQ14NP07519 Introduction: Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body s own

More information

A Local Stability of Mathematical Models for Cancer Treatment by Using Gene Therapy

A Local Stability of Mathematical Models for Cancer Treatment by Using Gene Therapy International Journal of Modeling Optimization, Vol 5, No 3, June 2015 A Local Stability of Mathematical Models for Cancer Treatment by Using Gene Therapy Dwi Lestari Ratnasari Dwi Ambarwati Abstract This

More information

Monoclonal Antibodies in Cancer. Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc.

Monoclonal Antibodies in Cancer. Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc. Monoclonal Antibodies in Cancer Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc. Disclaimer I had nothing to do with Herceptin Using lessons learned in new antibody projects

More information

Chemotherapy resistance in acute myeloid leukemia: the role of adhesion

Chemotherapy resistance in acute myeloid leukemia: the role of adhesion Chemotherapy resistance in acute myeloid leukemia: the role of adhesion Joe C. Huang, M.D. Research Elective 8/09-10/09 Mentor: Pamela S. Becker, M.D., Ph.D. Associate Professor of Medicine/Hematology

More information

Microbiology AN INTRODUCTION EIGHTH EDITION

Microbiology AN INTRODUCTION EIGHTH EDITION TORTORA FUNKE CASE Microbiology AN INTRODUCTION EIGHTH EDITION Differentiate between innate and acquired immunity. Chapter 17 Specific Defenses of the Host: The Immune Response B.E Pruitt & Jane J. Stein

More information

Rome, 9-10 June 2016

Rome, 9-10 June 2016 Rome, 9-10 June 2016 1 Exosomes in pathological conditions AICC SCIENTIFIC BOARD President Katia Scotlandi, IRCCS Rizzoli Orthopaedic Institute, Bologna VicePresident Michele Caraglia, Second University

More information

The Types of stem cells: Totipotent Pluripotent Multipotent

The Types of stem cells: Totipotent Pluripotent Multipotent Stem Cells is the main material for building and regeneration of the body Stem cells are not differentiated and can transform to any cell of organism Stem cells are capable of indefinite renewal through

More information

Course Curriculum for Master Degree in Clinical Pharmacy

Course Curriculum for Master Degree in Clinical Pharmacy Course Curriculum for Master Degree in Clinical Pharmacy The Master Degree in Clinical Pharmacy is awarded by the Faculty of Graduate studies at Jordan University of Science and Technology (JUST) upon

More information

27 th. Annual Conference. 27 th Annual Conference of Italian Association of Cell Cultures (ONLUS-AICC)

27 th. Annual Conference. 27 th Annual Conference of Italian Association of Cell Cultures (ONLUS-AICC) ASSOCIAZIONE ITALIANA DI COLTURE CELLULARI Onlus UNIVERSITÀ DEGLI STUDI DI VERONA Dipartimento Scienze della Vita e della Riproduzione Sezione di Chimica Biologica 27 th Annual Conference of Italian Association

More information

Stem Cell Information

Stem Cell Information Stem Cell Information The official National Institutes of Health resource for stem cell research Stem Cell Basics Stem cells have the remarkable potential to develop into many different cell types in the

More information

Umbilical Cord Blood Stem Cells Current Status & Future Potential

Umbilical Cord Blood Stem Cells Current Status & Future Potential Umbilical Cord Blood Stem Cells Current Status & Future Potential Natasha Ali Assistant Professor Haematology Department of Pathology & Laboratory Medicine/Oncology The Aga Khan University Email: natasha.ali@aku.edu

More information

In Vitro And In Vivo Production Of Antibodies

In Vitro And In Vivo Production Of Antibodies In Vitro And In Vivo Production Of Antibodies OCTOBER 27, 2015 BY ADMIN Overview An antibody is a protein normally produced by the B cells of the immune system. Their original purpose is to identify and

More information

National Workshop of Hematology The TP53 Workshop

National Workshop of Hematology The TP53 Workshop National Workshop of Hematology The TP53 Workshop Bologna, 10 th May 2013 Aemilia Hotel Via G. Zaccherini Alvisi, 16 Bologna PROMOTED BY Workshop Presidents Michele Cavo Giovanni Martinelli Pier Luigi

More information

Chapter 17A: Adaptive Immunity Part I

Chapter 17A: Adaptive Immunity Part I Chapter 17A: Adaptive Immunity Part I 1. Overview of Adaptive Immunity 2. T and B Cell Production 3. Antigens & Antigen Presentation 4. Helper T cells 1. Overview of Adaptive Immunity The Nature of Adaptive

More information

So, get comfortable and enjoy finding out what the greatest achievements and challenges are facing the industry today.

So, get comfortable and enjoy finding out what the greatest achievements and challenges are facing the industry today. 1 Who is the most influential figure in cord blood around the world? What do you think has been the biggest achievement within the cord blood sector? Which is the most important development in cord blood

More information

Fighting the Battles: Conducting a Clinical Assay

Fighting the Battles: Conducting a Clinical Assay Fighting the Battles: Conducting a Clinical Assay 6 Vocabulary: In Vitro: studies in biology that are conducted using components of an organism that have been isolated from their usual biological surroundings

More information

The use of monoclonal antibodies in the setting of HSCT

The use of monoclonal antibodies in the setting of HSCT The use of monoclonal antibodies in the setting of HSCT S Montoto, Barts Cancer Institute, London, UK Geneva 3/April/2012 www.ebmt.org Some definitions of interest: Ab and Ag Antibody (Ab)=Immunoglobulin

More information

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including

More information

Custom Antibody Services

Custom Antibody Services prosci-inc.com Custom Antibody Services High Performance Antibodies and More Broad Antibody Catalog Extensive Antibody Services CUSTOM ANTIBODY SERVICES Established in 1998, ProSci Incorporated is a leading

More information

College of Pharmacy & Pharmaceutical Sciences Graduate Catalog 2015-2016

College of Pharmacy & Pharmaceutical Sciences Graduate Catalog 2015-2016 College of Pharmacy & Pharmaceutical Sciences Graduate Catalog 2015-2016 Degrees Offered Doctor of Philosophy in Experimental Therapeutics Doctor of Philosophy in Medicinal Chemistry Master of Science

More information